Skip to main content
Log in

Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Albiglutide (Eperzan®, Tanzeum®), administered subcutaneously once weekly, is a glucagon-like peptide (GLP)-1 receptor agonist approved for the treatment of type 2 diabetes mellitus in several countries. Albiglutide has a longer half-life than native GLP-1, since it is resistant to degradation by the dipeptidyl peptidase-4 enzyme. As an incretin mimetic, albiglutide enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, delays gastric emptying and reduces food intake. Several phase III clinical trials have demonstrated the efficacy of albiglutide in terms of improving glycaemic control in patients with inadequately controlled type 2 diabetes, including its use as monotherapy or add-on therapy to other antidiabetic agents (e.g. metformin, sulfonylureas, thiazolidinediones and insulins). In addition to improving glycaemic control, albiglutide had beneficial effects on bodyweight. These improvements in glycaemic control and reductions in bodyweight were maintained during long-term treatment (up to 3 years). Albiglutide was generally well tolerated in clinical trials, with mild to moderate gastrointestinal adverse events seen most commonly. Albiglutide has a convenient once-weekly administration regimen and a low risk of hypoglycaemia (except when used in combination with agents that may be associated with hypoglycaemia, such as sulfonylureas or insulin). Thus, albiglutide is an effective and generally well tolerated treatment option for patients with inadequately controlled type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl. 1):S14–80.

    Article  Google Scholar 

  2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–96.

    Article  CAS  PubMed  Google Scholar 

  3. Baggio LL, Huang Q, Brown TJ, et al. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004;53(9):2492–500.

    Article  CAS  PubMed  Google Scholar 

  4. Bush MA, Matthews JE, De Boever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009;11(5):498–505.

    Article  CAS  PubMed  Google Scholar 

  5. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig. 2013;4(2):108–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126–31.

    Article  CAS  PubMed  Google Scholar 

  7. European Medicines Agency. Eperzan (albiglutide): summary of product characteristics. 2014. http://www.ema.europa.eu. Accessed 26 Feb 2015.

  8. GlaxoSmithKline. Tanzeum (albiglutide): US prescribing information. 2014. http://www.accessdata.fda.gov. Accessed 26 Feb 2015.

  9. Young MA, Wald JA, Matthews JE, et al. Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgrad Med. 2014;126(7):84–97.

    Article  PubMed  Google Scholar 

  10. Trujillo JM, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014;48(11):1494–501.

    Article  CAS  PubMed  Google Scholar 

  11. Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett. 2013;23(14):4011–8.

    Article  CAS  PubMed  Google Scholar 

  12. Hompesch M, Jones-Leone A, Carr MC, et al. Albiglutide does not impair the counter-regulatory hormone response to hypoglycemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2014.

  13. Seino Y, Inagaki N, Miyahara H, et al. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Curr Med Res Opin. 2014;30(6):1095–106.

    Article  CAS  PubMed  Google Scholar 

  14. Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32(10):1880–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin. 2009;25(12):3049–57.

    Article  CAS  PubMed  Google Scholar 

  16. European Medicines Agency. Eperzan assessment report. 2014. http://www.ema.europa.eu. Accessed 26 Feb 2015.

  17. Rosenstock J, Stewart MW. Albiglutide. Drugs Future. 2010;35(9):701–12.

    Article  CAS  Google Scholar 

  18. Darpo B, Zhou M, Matthews J, et al. Albiglutide does not prolong QTc interval in healthy subjects: a thorough ECG study. Diabetes Ther. 2014;5(1):141–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Bao W, Aravindhan K, Alsaid H, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One. 2011;6(8):e23570.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810–7.

    Article  CAS  PubMed  Google Scholar 

  21. Bush MA, Smith C, Watanalumlerd P, et al. Population pharmacokinetic (PK) analysis of albiglutide in a phase IIb study in japanese patients with type 2 diabetes [abstract no. 1020-P]. Diabetes. 2012;61(Suppl. 1):A261–2.

    Google Scholar 

  22. Bush M, Scott R, Watanalumlerd P, et al. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012;124(6):55–72.

    Article  PubMed  Google Scholar 

  23. Reusch J, Stewart MW, Perkins CM, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014;16(12):1257–64.

    Article  CAS  PubMed  Google Scholar 

  24. Reinhardt R, Nauck MA, Stewart M, et al. HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise [abstract no. 903]. In: 49th Annual Meeting of the European Association for the Study of Diabetes; 2013.

  25. Ahren B, Johnson SL, Stewart M, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141–8.

    Article  CAS  PubMed  Google Scholar 

  26. Weissman PN, Carr MC, Ye J, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014;57(12):2475–84.

    Article  CAS  PubMed  Google Scholar 

  27. Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37(8):2317–25.

    Article  CAS  PubMed  Google Scholar 

  28. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2(4):289–97.

    Article  CAS  PubMed  Google Scholar 

  29. Leiter LA, Carr MC, Stewart M, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37(10):2723–30.

    Article  CAS  PubMed  Google Scholar 

  30. Home PD, Shamanna P, Stewart M, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab. 2014.

  31. Carr MC, Rendell M, Scott RA, et al. Harmony 2 year 3 results: albiglutide monotherapy in drug naive patients with type 2 diabetes mellitus [abstract no. 830 plus poster]. In: 50th Annual Meeting of the European Association for the Study of Diabetes; 2014.

  32. Martin AA, Johnson SL, Ye J. Treatment satisfaction with albiglutide and liraglutide in patients with type 2 diabetes uncontrolled with oral therapy [abstract no. 1010-P]. In: 73rd Annual Scientific Sessions of the American Diabetes Association; 2013.

  33. Bode BW, Stewart M, Cirkel D, et al. Harmony 1 year 3 results: albiglutide vs. placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone (Pio) + metformin (Met) [abstract no. 960-P plus poster]. In: 74th Scientific Sessions of the American Diabetes Association; 2014.

  34. Matthews JE, Ahren B, Ye J, et al. Harmony 3 year 3 results: albiglutide vs sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin [abstract no. 831 plus poster]. In: 50th Annual Meeting of the European Association for the Study of Diabetes; 2014.

  35. Shamanna P, Home P, Stewart MW, et al. Harmony 5-year 3 results: albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes [abstract no. 838 plus poster]. In: 50th Annual Meeting of the European Association for the Study of Diabetes; 2014.

  36. Weissman PN, Stewart MW, Cirkel DT, et al. Harmony 4: 3 year efficacy of albiglutide (ALBI) vs insulin glargine (GLAR) in patients with type 2 diabetes mellitus [abstract no. 837 plus poster]. In: 50th Annual Meeting of the European Association for the Study of Diabetes; 2014.

  37. Martin AA, Johnson SL, Ye J, et al. Improved treatment satisfaction with weekly abiglutide vs. thrice daily prandial insulin added to insulin glargine in type 2 diabetes [abstract no. 2590-PO]. In: 73rd Scientific Sessions of the American Diabetes Association; 2013.

  38. Fonseca VL, Ahren B, Chow F, et al. Once weekly GLP-1 receptor agonist albiglutide vs prandial lispro added to basal glargine in type 2 diabetes: similar glycaemic control with weight loss and less hypoglycaemia [abstract no. 581]. In: 48th Annual Meeting of the European Association for the Study of Diabetes 2012.

  39. Nino AJ, Davidson JA, Scott RA, et al. Albiglutide efficacy and safety in the African/African American subpopulation from the integrated phase III program [abstract no. 1003-P plus poster]. In: 74th Scientific Sessions of the American Diabetes Association; 2014.

  40. Davidson JA, Jones-Leone A, Wilson TH, et al. Albiglutide efficacy and safety in the Hispanic/Latino subpopulation from the integrated phase III program [abstract no. 1004-P plus poster]. In: 74th Scientific Sessions of the American Diabetes Association; 2014.

  41. Mallory JM, Leiter LA, Wilson TH, et al. Gastrointestinal safety across the albiglutide development program [abstract no. 1002-P plus poster]. Diabetes. 2014;63(Suppl. 1):A257–8.

    Google Scholar 

  42. Ambery PD, Donaldson J, Ye J, et al. Results of the albiglutide HARMONY program prospective major adverse cardiovascular event (MI, stroke, cardiovascular death, and unstable angina) meta-analysis [abstract no. 908 plus poster]. Diabetologia. 2014;57(Suppl. 1):S370.

    Google Scholar 

  43. Johnson S, Nauck MA, Zhi H, et al. Integrated phase 3 immunogenicity results for albiglutide [abstract no. 1640-P plus poster]. Diabetes. 2014;63(Suppl. 1):A427.

    Google Scholar 

  44. Ross SA, Dzida G, Vora J, et al. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin. 2011;27(7):1431–8.

    Article  PubMed  Google Scholar 

  45. Sisley S, Gutierrez-Aguilar R, Scott M, et al. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest. 2014;124(6):2456–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473–88.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Tzefos M, Harris K, Brackett A. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother. 2012;46(1):68–78.

    Article  CAS  PubMed  Google Scholar 

  48. Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013;126(9 Suppl 1):S38–48.

    Article  PubMed  Google Scholar 

  49. Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97(1):121–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care. 2013;36(Suppl 2):S245–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534–9.

    Article  CAS  PubMed  Google Scholar 

  52. Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab. 2012;14(12):1123–8.

    CAS  PubMed  Google Scholar 

  53. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370(9):794–7.

    Article  CAS  PubMed  Google Scholar 

  54. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Investig. 2014;5(5):475–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13(2):144–9.

    Article  CAS  PubMed  Google Scholar 

  57. Leiter LA, Scott RA, Ye J, et al. Medication compliance rates of weekly albiglutide vs. daily oral comparators in phase III trials [abstract no. 994-P plus poster]. In: 74th Scientific Sessions of the American Diabetes Association; 2014.

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit. Hannah Blair and Gillian Keating are salaried employees of Adis/Springer.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hannah A. Blair.

Additional information

The manuscript was reviewed by: D. S. H. Bell, Southside Endocrinology, University of Alabama, Birmingham, AL, USA; K. Kaku, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan; Y. Seino, Kansai Electric Power Hospital, Osaka, Japan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blair, H.A., Keating, G.M. Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75, 651–663 (2015). https://doi.org/10.1007/s40265-015-0370-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0370-5

Keywords

Navigation